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Mitochondrial uncoupling links lipid catabolism to
Akt inhibition and resistance to tumorigenesis
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To support growth, tumour cells reprogramme their metabolism to simultaneously upregulate
macromolecular biosynthesis while maintaining energy production. Uncoupling proteins
(UCPs) oppose this phenotype by inducing futile mitochondrial respiration that is uncoupled
from ATP synthesis, resulting in nutrient wasting. Here using a UCP3 transgene targeted to
the basal epidermis, we show that forced mitochondrial uncoupling inhibits skin carcino-
genesis by blocking Akt activation. Similarly, Akt activation is markedly inhibited in UCP3
overexpressing primary human keratinocytes. Mechanistic studies reveal that uncoupling
increases fatty acid oxidation and membrane phospholipid catabolism, and impairs
recruitment of Akt to the plasma membrane. Overexpression of Akt overcomes metabolic
regulation by UCP3, rescuing carcinogenesis. These findings demonstrate that mitochondrial
uncoupling is an effective strategy to limit proliferation and tumorigenesis through inhibition
of Akt, and illuminate a novel mechanism of crosstalk between mitochondrial metabolism and
growth signalling.
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I
n the last decade, researchers have renewed efforts to
understand the nearly century-old observation that tumour
cells undergo a metabolic switch, implementing aerobic
glycolysis (also known as the Warburg Effect) and suppressing
mitochondrial oxidative phosphorylation1. We now appreciate
that tumour cells’ seemingly paradoxical reliance on the less
efficient process of glycolysis for generation of ATP likely confers
a growth advantage, by allowing cells to balance the need to
produce energy with the need to produce biomass. In addition to
upregulating glycolysis, changes in mitochondrial function appear
to re-direct nutrient utilization away from substrate oxidation
and towards biosynthesis, allowing mitochondria to provide
metabolic precursors for the construction of nucleotides, proteins
and lipids2,3. This crucial restructuring of tumour cell metabolism
is controlled by classical oncoproteins and tumour suppressors,
such as c-myc, hypoxia inducible factors, p53, mammalian target
of rapamycin (mTOR), phosphatidylinositol 3-kinase (PI3K) and
Akt (protein kinase B)4,5.
Akt is a serine/threonine kinase that is one of the most
commonly upregulated oncoproteins in a variety of cancers.
Activated in response to mitogens such as epidermal growth
factor (EGF), Akt phosphorylates a myriad of proteins involved in
protein translation, metabolism, cell survival/anti-apoptosis and
cell cycle progression, including among others glycogen synthase
kinase-3a/b (GSK-3a/b), Forkhead box protein O (FOXO)
transcription factors, tuberin/tuberous sclerosis 2 (TSC2),
p21 (Cip1/Waf1) and p27 (Kip1; refs 6,7). Simultaneously,
Akt controls proliferation in part by driving metabolic
reprogramming characterized by increased glucose uptake8,
glycolytic rate and lactate production9, and de novo lipid
synthesis10, along with suppression of macromolecular
degradation11,12. In addition to the regulation of cellular
metabolism by growth signalling, metabolic changes are well
known to exert reciprocal control of growth signalling pathways
(for example, mTOR)4. In contrast to its well-established role
in metabolic regulation, there is a paucity of information
regarding whether and how metabolic state modulates Akt
signalling.
One effective strategy to drive nutrient oxidation and limit
energy production is to decrease the efficiency of mitochondrial
oxidative phosphorylation through proton leak. Mitochondrial
uncoupling proteins (UCPs) are evolutionarily conserved,
nuclear-encoded members of the mitochondrial solute carrier
superfamily that increase proton leak across the inner mito-
chondrial membrane in a variety of tissues, including brown fat,
heart, skeletal muscle and most recently, skin13–15. Also referred
to as mitochondrial uncoupling, the proton leak generated
by UCPs disengages fuel oxidation and electron transport
from ATP synthesis, and as a result, uncoupled cells increase
substrate oxidation and electron transport in an effort to
maintain mitochondrial membrane potential16,17. Given that
mitochondrial uncoupling drives catabolic metabolism, contrary
to the anabolic needs of cancer cells, we hypothesized that driving
this process would oppose tumorigenesis. As proof of principle,
we previously published that overexpression of UCP3 blocked
chemically mediated skin carcinogenesis18. Here we show that
the mechanism underlying uncoupling-induced resistance to
tumour formation involves the marked inhibition of tumour
promotion through blockade of PI3K/Akt signalling. We
demonstrate that enforced mitochondrial uncoupling enhances
lipid catabolism and membrane phospholipid breakdown,
causing the accumulation of lysophospholipid by-products, and
restricting Akt membrane recruitment and activity. Furthermore,
overexpression of wild-type Akt in the presence of UCP3 rescues
two-stage chemical carcinogenesis. These results establish a
mechanism for UCP3-induced chemoresistance, and identify a
unique pathway of metabolic Akt regulation that could be
exploited by future therapeutic strategies.
Results
UCP3 expression blocks tumour promotion. We previously
generated K5-UCP3mice that overexpress murine UCP3, targeted
to the basal epidermis by the bovine keratin 5 promoter (K5;
ref. 18). K5-UCP3 basal keratinocytes exhibit proper localization
of UCP3 in the mitochondria, and compared with wild type,
K5-UCP3 epidermis exhibits an approximately twofold increase
in uncoupled per total respiration, indicating that the transgenic
mitochondria are uncoupled, and the K5-UCP3 transgene is
functional18. To further validate this observation, we quantified
mitochondrial membrane potential in isolated primary
keratinocytes using tetramethylrhodamine methyl ester (TMRM)
staining, and flow cytometry. Staining with the non-
potentiometric indicator MitoTracker Green (MTG) was used
as a control to normalize for increases in mitochondrial mass, as
previously described (ibid). This analysis revealed decreased
mitochondrial membrane potential in K5-UCP3 primary
keratinocytes (Supplementary Fig. 1a). Furthermore, we
observed a 20% decrease in ATP levels in K5-UCP3 isolated
primary keratinocytes compared with wild type (Supplementary
Fig. 1b). Taken together, these experiments confirmed that
K5-UCP3mitochondria display hallmarks of increased uncoupling,
in agreement with previously published observations18.
Using a two-stage chemical carcinogenesis regimen, we
previously showed that K5-UCP3 mice were exceptionally
resistant to skin tumour formation18. In support of the idea
that this resistance resulted from mitochondrial uncoupling,
we performed complementary analyses in mice engineered to
ectopically express the prototypical UCP1, also targeted to the
basal epidermis (K5-UCP1). K5-UCP1 mice were also resistant
to tumour formation in response to a two-stage chemical
carcinogenesis regimen (Supplementary Fig. 1c-f), strongly
suggesting that resistance to tumorigenesis in these transgenic
models resulted from mitochondrial uncoupling.
To test whether UCP3 confers resistance to tumorigenesis
mainly through effects on tumour initiation or tumour promo-
tion, and to test the effect of UCP3 overexpression on tumour
formation in a genetic model, we crossed K5-UCP3 animals with
‘pre-initiated’ Tg.AC mice, which harbour an oncogenic v-Ha-Ras
transgene19. In response to topical application of the tumour
promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) (treatment
timeline Fig. 1a), Tg.AC mice rapidly formed tumours; however,
bi-transgenic K5-UCP3/Tg.AC mice phenocopied the potent
resistance to tumour formation observed in the K5-UCP3
background (Fig. 1b–e), indicating that UCP3 overexpression
likely interferes with tumour promotion.
Consistent with this phenotype, 5-bromo-2-deoxyuridine
(BrdU) labelling revealed that UCP3 overexpression dramatically
reduced the proliferative response to both single (1 ) and
multiple (4 ) TPA treatments by B80% (Fig. 1f). Whereas both
1 and 4 TPA treatment induced a 7.3–7.8-fold increase in
labelling index in wild-type FVB/N epidermis compared with
acetone (vehicle control), labelling index in K5-UCP3 epidermis
only increased by 1.37 and 1.62-fold in response to 1 and 4
TPA treatment, respectively (Fig. 1g).
UCP3 expression inhibits Akt activation. Following TPA
treatment, activation of numerous cell growth signalling pathways
converges at the induction of cyclins and suppression of cell cycle
inhibitory proteins to induce cell proliferation7,20. Consistent
with the observed lack of TPA-induced proliferation in K5-UCP3
epidermis, 18 h after TPA treatment, K5-UCP3 epidermis showed
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blunted cyclin D1 and cyclin A induction, and maintenance of
p21 and p27 levels (Fig. 2a). To further understand which
pathway(s) were involved in this effect, we performed a wide
analysis of growth signalling pathways in K5-UCP3 epidermis via
western blotting. Many pathways, including b-catenin, STAT3
and JNK, maintained activation levels similar to that seen in wild-
type epidermis (Supplementary Fig. 2a,b). However, activation of
Akt was markedly inhibited in K5-UCP3 epidermis, as indicated
by decreased phosphorylation at both S473 (mTORC2 site) and
T308 (PDK1 site) compared with wild-type epidermis (Fig. 2a,b).
This effect corresponded to decreased phosphorylation of direct
Akt targets, including GSK-3b and FOXO1 (Fig. 2b), as well as
TSC2 (Fig. 2c).
Given the well-established relationships between metabolic
state and mTOR activation, along with the observed lack of
Akt activation, we predicted that UCP3 overexpression should
correspond to decreased activation of mTOR. Surprisingly,
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Figure 1 | UCP3 overexpression impedes tumour promotion. (a) Timeline (in weeks) for Tg.AC tumour experiment. Sixteen-week old mice (Tg.AC, n¼ 20,
K5-UCP3/Tg.AC, n¼ 20) were shaved dorsally and treated with bi-weekly applications of TPA (2.5 mg) for 2 weeks for a total of four treatments. Week ‘0’
indicates first TPA application. (b) Tumour development in ‘pre-initiated’ Tg.AC and bigenic K5-UCP3/Tg.AC mice indicating total papillomas per mouse,
(c) % mice bearing papillomas, (d) total carcinomas per mouse, and (e) % mice bearing carcinomas. (f) Immunohistochemistry for BrdU labelled cells in
wild-type FVB and K5-UCP3 epidermis following topical treatment with acetone (vehicle control), single (1 ) or multiple (4 ) treatments with 2.5mg
TPA. Scale bars, 50microns. (g) Quantification of percentage of BrdU-positive labelled cells in the basal layer of the interfollicular epidermis. Error bars
represent meansþ / s.e.m. (n¼ 3 animals per group). *Indicates significantly different from acetone control, same genotype (**Po0.01, ***Po0.0001,
one way analysis of variance followed by Dunnett’s post hoc analysis), w indicates significantly different from wild-type FVB, same treatment
(wwwPo0.0001, Student’s t-test).
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or slightly diminished, and mTOR auto-phosphorylation at
S2481 was unaffected. Furthermore, phosphorylation of targets
downstream of mTORC1, including ribosomal protein S6 (rS6),
eukaryotic translation initiation factor 4E-binding protein 1
(4EBP1), and eukaryotic initiation factor 4G (eIF4G) was not
markedly decreased, implying that UCP3 induces complex
metabolic regulation of mTOR (Fig. 2c). The ability of TPA to
activate mTOR despite the absence of Akt activity in K5-UCP3
epidermis is perhaps somewhat paradoxical, and warrants
further investigation into possible alternative mechanisms of
mTOR activation in response to TPA treatment. Although these
effects on mTOR are interesting, the data point toward an
mTOR-independent mechanism of resistance to tumorigenesis
in K5-UCP3 mice because activation of mTOR and its


















































































































Figure 2 | UCP3 overexpression inhibits Akt activation. (a) Immunoblot for Akt phosphorylation at Ser 473, along with total Akt, Cyclin D1 and Cyclin A
expression, and cell cycle inhibitory proteins p21 (Cip1/Waf1) and p27 (Kip1) expression following treatment with acetone (vehicle control, 4-h post
treatment) or 2.5mg TPA (4 and 18-h post treatment) in wild-type FVB and K5-UCP3 epidermal lysates. (b) Akt phosphorylation at Ser 473 and Thr 308,
along with phosphorylation of Akt targets FOXO1 at Ser 256 and Ser 319, and GSK3b at Ser 9 in wild-type FVB and K5-UCP3 epidermal lysates, following
topical treatment with 2.5mg TPA or acetone. (c) Phosphorylation of mTORC1 pathway members TSC2 (Ser 939), mTOR (Ser 2448, Ser 2481), 4EBP1
(Thr 36/47), ribosomal S6 (Thr 240/244) and eIF4G (Ser 1108) in wild-type FVB and K5-UCP3 epidermal lysates following topical treatment with 2.5-mg
TPA or acetone. (d) Phosphorylation of Akt Ser 473 and (e) phosphorylation of EGFR (Ser 1086) in serum starved wild-type FVB and K5-UCP3 primary
epidermal keratinocytes, after treatment with 40 ngml 1 EGF or 0.001% BSA (vehicle control) at the indicated time points. (f) Phosphorylation of Akt Ser
473 in primary neonatal human keratinocytes transiently transfected with UCP3 or empty vector control (EV) and treated with 40ngml 1 EGF or 0.001%
BSA. Immunoblot for UCP3 confirmed successful transfection. (g) In vitro PP2A catalytic activity, expressed as fold change compared with wild type.
Immunoprecipitated PP2Ac was incubated with a target phosphopeptide and free phosphate release was measured using a malachite green assay and
absorbance at 620 nm. Error bars represent meansþ / s.e.m. (n¼4 biological replicates). ***Indicates significantly different from wild type (Po0.001,
Student’s t-test). (h) Immunoblot for Akt Ser 473 and p38 MAPK T180/Y182 phosphorylation in wild-type FVB and K5-UCP3 epidermal lysates 1 h
following topical treatment with 5-nmol okadaic acid or acetone (vehicle control). b-Actin or a-Tubulin confirmed equal loading (a-f,h).
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TPA acts in large part as a diacylglycerol mimetic, binding
protein kinase C (PKC) isoforms and activating subsequent
downstream signalling, which, among numerous other effects,
increases EGF ligand expression and ectodomain cleavage,
resulting in paracrine/autocrine signalling21,22. Studies using
both chemical inhibitors and dominant negative mutants have
shown that EGF receptor (EGFR) activation is necessary for
TPA-induced activation of Akt and other pathways23–25. To rule
out the possibilities that UCP3 overexpression prevented TPA-
induced Akt activation via inhibition of PKC and/or impaired
EGF ligand shedding, we evaluated Akt activation in serum
starved, isolated primary keratinocytes treated with EGF. As
expected, K5-UCP3 cells showed blunted Akt activation after EGF
treatment (Fig. 2d). In contrast, EGFR activation was unaffected
by UCP3, despite slightly lower total receptor expression (Fig. 2e).
Importantly, UCP3 expression also blocked activation of Akt by
EGF in primary neonatal human keratinocytes (Fig. 2f). Together,
these observations demonstrate that the UCP3-dependent
regulation of Akt activity occurs downstream of EGFR
activation in a cell autonomous, species-independent manner.
Subsequent to EGFR activation, PI3K converts phosphatidyli-
nositol 4,5-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-
trisphosphate (PIP3), resulting in the recruitment of Akt to the
plasma membrane. To define the mechanisms by which UCP3
blunts Akt signalling downstream of EGFR activation, we initially
focused on phosphatase and tensin homologue (PTEN), a tumour
suppressor lipid phosphatase that converts PIP3 back to PIP2,
thereby inhibiting Akt. PTEN activity can be regulated by changes
in expression, or in the stabilizing phosphorylation of its
C-terminal tail, which increases its activity. Levels of both
phosphorylated and total PTEN protein were unchanged in
K5-UCP3 compared with wild-type epidermis, ruling out the
likelihood that changes in PTEN function account for
UCP3-induced blockade of Akt activation (data not shown).
We then examined another negative regulator of Akt
activation, protein phosphatase 2A (PP2A), a serine/threonine
phosphatase that dephosphorylates Akt at both S473 and T308
(ref. 26). Although the expression of PP2A A (scaffolding) and C
(catalytic) subunits was unchanged from wild type to K5-UCP3
epidermis (Supplementary Fig. 2c), several additional prominent
PP2A targets, including p38-mitogen activated protein kinase
(p38 MAPK), showed a pattern of reduced phosphorylation in
K5-UCP3 epidermal lysates (Supplementary Fig. 2d), implying
that PP2A was hyper-active in K5-UCP3 epidermis. Indeed, using
an in vitro activity assay, K5-UCP3 samples showed a significant
but modest increase in PP2A catalytic activity (39%) compared
with wild-type controls (Fig. 2g). Topical treatment with the
PP2A inhibitor okadaic acid (OA) was able to completely recover
phosphorylation of p38 MAPK, however, OA only partially
rescued Akt phosphorylation in K5-UCP3 epidermis (Fig. 2h).
Thus, PP2A hyperactivity likely contributes to, but is not solely
responsible for the UCP3-induced blockade of PI3K/Akt
signalling. However, the striking effects on other PP2A targets,
including p38 MAPK, may inform future studies detailing
additional Akt-independent pleiotropic mechanisms of
UCP3-induced inhibition of tumorigenesis.
UCP3 expression alters lipid homoeostasis. Because PP2A
hyperactivity could not fully explain the UCP3-dependent
inhibition of Akt, we focused on two main functions of UCP3: its
ability to decrease reactive oxygen species (ROS) generation17,
and increase lipid metabolism27. Some evidence suggests that
ROS regulate both PP2A and Akt28,29, therefore, we hypothesized
that UCP3 overexpression may inhibit Akt through redox
regulation. However, we neither detected a significant difference
in either cellular ROS or ROS released from isolated
mitochondria, nor did we observe a change in the oxidation
state of either PP2A or Akt thiols in response to uncoupling
(Supplementary Fig. 3).
Because the levels of ROS were similar in wild type and
K5-UCP3 cells and mitochondria, we next used an unbiased
metabolomics approach to holistically examine changes in
cellular metabolism in K5-UCP3 epidermis. This wide analysis
revealed changes in large classes of nutrient metabolites indicative
of increases in several catabolic pathways. We observed decreased
levels of six-carbon glycolytic intermediates and increased levels
of three-carbon glycolytic intermediates in K5-UCP3 epidermis,
consistent with increased glycolysis (Supplementary Fig. 4a). In
contrast, we observed no significant changes in any TCA cycle
intermediates, although these steady state data may not be
representative of any potential changes in flux through the TCA
cycle (Supplementary Fig. 4b). We also observed a trend towards
decreased levels of glutamine and glutamate in K5-UCP3
epidermis, however, this difference was not statistically significant
(Supplementary Fig. 4b). These results are intriguing, as tumour
cells often also upregulate glycolysis to provide precursors for
macromolecular biosynthesis, hence increased glycolysis in a
tumour resistant model might seem paradoxical on the surface.
However, we also found that UCP3 overexpression resulted in the
breakdown of macromolecules necessary for cell proliferation,
such as phospholipids.
Arguably, the largest class effect observed in response to UCP3
expression was increased lipid catabolism in K5-UCP3 epidermis,
characterized by decreased steady-state levels of free fatty acids
(Fig. 3a), and long chain acyl-carnitine species (Fig. 3b).
Concurrently, K5-UCP3 epidermis displayed increased levels of
lysophospholipids, which are formed by cleavage of a single acyl
chain during phospholipid breakdown, suggesting that uncoupled
cells scavenge fatty acid tails from membrane lipids as substrates
for b-oxidation (Fig. 3c). Consistent with the idea that UCP3
induced global lipid breakdown rather than oxidation of a specific
lipid species or activation of a specific phospholipase, neither the
decreases in free fatty acids, nor the increases in lysophospholipid
levels followed any discernible pattern in terms of chain length,
saturation or head group composition (Fig. 3, Supplementary
Fig. 5). Although we observed similar levels of total cellular
lipid levels in isolated keratinocytes via nile red staining
(Supplementary Fig. 6), given the strength of our metabolomics
data, we decided to further explore the effect of UCP3
overexpression on lipid metabolism in K5-UCP3 epidermis.
K5-UCP3 primary keratinocytes showed no change in fatty acid
uptake (data not shown) relative to wild-type keratinocytes, but
K5-UCP3 epidermis had significantly increased fatty acid
oxidation compared with wild type (Fig. 4a), supporting the
notion that K5-UCP3 keratinocytes scavenge fats from intra-
cellular lipid stores. Similarly, gene expression profiling demon-
strated the significant up-regulation of numerous fatty acid
metabolism genes in K5-UCP3 skin (Supplementary Table 1).
Studies have indicated that changes in b-oxidation can reshape
plasma membrane lipid composition30,31, and UCP3 is well
known for its ability to increase b-oxidation of lipids27. Therefore,
we reasoned that UCP3 overexpression might affect Akt
activation by promoting the oxidation of fatty acids and
modifying membrane composition. To test whether these
changes in lipid homoeostasis corresponded to functional
differences in membrane recruitment of Akt, we isolated
epidermal membranes from acetone and TPA treated mice. As
predicted, less Akt was present in the membrane fraction from
TPA treated K5-UCP3 epidermis compared with wild type
(Fig. 4b,c). Of note, in the same assay we observed similar
levels of Protein Kinase C and PTEN membrane localization in
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wild type and K5-UCP3 epidermis, another indication that the
activity of these proteins is unchanged (Fig. 4b). Combined, these
results suggest the possibility that UCP3-induced lipid catabolism
may alter plasma membrane composition and dynamics, thereby
impeding Akt membrane recruitment.
To establish the capacity of mitochondrial b-oxidation to affect
Akt signalling, we treated mice with the carnitine-palmitoyl
transferase inhibitor etomoxir (Eto) at a dose previously shown to
inhibit mitochondrial fatty acid uptake by roughly 50% when
applied topically32. Not only did Eto treatment augment basal Akt
activation in K5-UCP3 epidermis, it also did so in wild-type
epidermis, demonstrating that fatty acid oxidation is a novel
regulator of Akt signalling (Fig. 4d).
Akt overexpression rescues tumorigenesis. To establish the
functional importance of UCP3-mediated changes in lipid
homoeostasis and Akt activation in UCP3-induced resistance to
tumour formation, we inter-bred K5-UCP3 animals with mice
that over-express an epidermally targeted, wild-type Akt trans-
gene (K5-Akt)33. Akt overexpression had no effect on epidermal
respiration (Supplementary Fig. 7); however, as previously
published, K5-Akt mice exhibited heightened Akt expression
and activation compared with wild type controls. Bi-transgenic
K5-UCP3/K5-Akt mice also displayed heightened Akt activation,
indicating that Akt overexpression alone was capable of
overcoming inhibition by UCP3 (Fig. 5a). In every treatment
group, Akt overexpression also increased epidermal proliferation
measured by BrdU incorporation, and rescued TPA-induced
proliferation in K5-UCP3/K5-Akt animals (Fig. 5b,c).
When subjected to a two-stage chemical carcinogenesis
regimen (Fig. 6a), Akt overexpression overcame metabolic
regulation and rescued skin tumorigenesis in K5-UCP3/K5-Akt
mice. Bi-transgenic K5-UCP3/K5-Akt mice and K5-Akt single
transgenics both formed more papillomas than wild-type mice,
and displayed nearly overlapping papilloma incidence curves
(Fig. 6b). Papilloma multiplicity revealed a slightly increased
latency before papilloma development in K5-UCP3/K5-Akt
animals; however, bi-transgenic mice still formed papillomas
more rapidly and abundantly than wild-type littermates (Fig. 6c).
K5-UCP3/K5-Akt mice also formed more carcinomas than wild-
type mice, however they still showed a significant reduction in
carcinoma formation compared with K5-Akt mice (Fig. 6d,e),
suggesting that UCP3 may also inhibit tumour progression, even
in the context of Akt overexpression. However, this difference
may be explained by the fact that the transgene can still be
regulated by the same changes that reduce endogenous Akt
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Figure 3 | Unbiased metabolomic analysis of K5-UCP3 epidermis reveals enhanced lipid catabolism. (a–c) Analysis of (a) fatty acid, (b) acylcarnitine
and (c) lysophospholipid metabolite levels in K5-UCP3 dorsal epidermis identified by gas chromatography mass spectrometry (GC–MS) or liquid
chromatography mass spectrometry (LC-MS), and expressed as fold change compared with wild-type FVB. Metabolites shown significantly differ from
wild-type with a P valueo0.05 (Welch’s t-test). Error bars represent meansþ / s.e.m. (n¼6 animals per group). All identified lipids are shown in
Supplementary Fig. 5.
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animal developed a carcinoma in the absence of the K5-Akt
transgene (Fig. 6d,e), in accordance with our previous findings18.
Taken together, these findings establish a new mitochondrial
pathway of metabolic Akt regulation that results in the profound
blockade of tumorigenesis via changes in fatty acid metabolism
and membrane homeostasis.
Discussion
While Otto Warburg originally proposed that mitochondrial
defects caused cancer, we now understand that metabolic
reprogramming likely confers tumour cells a growth advantage
by simultaneously supplying the energy and biomass necessary to
rapidly build new daughter cells. Here we show that enforced
mitochondrial uncoupling causes resistance to cancer formation,
likely as a result of pleiotropic changes in metabolism that
converge at least in part on Akt signalling. These results add to a
growing number of reports that suggest that manipulation of
mitochondrial metabolism and cellular energy balance has
profound effects on growth signalling. In contrast to the more
well-described pathways through which mitochondria can
regulate cellular proliferation through modulation of ATP, ROS
and amino-acid metabolism, the lipid-dependent regulation of
cell growth signalling is relatively less well understood.
Several indirect lines of evidence support our observation that
changes in cellular lipid homoeostasis control proliferation.
For example, in de novo lipogenesis, citrate is exported from
mitochondria and converted to cytoplasmic acetyl CoA by ATP
citrate lyase, the rate-limiting enzyme in lipid synthesis. Studies
have shown that inhibiting mitochondrial citrate export can block
the cell cycle34, and knockdown or inhibition of ATP citrate
lyase results in inhibition of PI3K/Akt signalling and
tumorigenesis35,36. Other reports have suggested that lipids can
affect Akt signalling through bioactive lipid signalling mediators,
such as sphingosine-1-phosphate, or through changes in
membrane composition and structure37,38. In addition,
lysophospholipids have been shown to affect membrane
recruitment and cellular signalling in an array of diverse
contexts39,40, however, the exact mechanisms are not well
understood. Future mechanistic studies are needed to further
detail how UCP3-induced lipid catabolism affects signalling
events and plasma membrane recruitment of Akt. Nonetheless,
along with the few reports cited above, our observations lay the
foundation and support an urgent need for greater exploration of
how lipid metabolism may control cell growth in general.
As noted above, overexpression of Akt in K5-UCP3/K5-Akt
mice rescued and augmented Akt phosphorylation beyond wild-
type levels. This suggests that the potential for Akt activation is
still intact in the presence of UCP3 overexpression. Several
possibilities exist to explain this observation. Despite the fact that
the K5-Akt transgene is a wild-type copy of Akt, we observed
strongly increased Akt phosphorylation in both K5-Akt and
K5-UCP3/K5-Akt epidermis even in the absence of TPA
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Figure 4 | Mitochondrial b-oxidation alters plasma membrane lipids and signaling. (a) Ex vivo epidermal fatty acid dependent respiration, fatty acid
independent respiration and total respiration measured by oxygen consumption in the presence or absence of Etomoxir (Eto) treatment. Fatty acid
dependent respiration was defined as the difference between total respiration and Eto inhibited (fatty acid independent) respiration. Error bars represent
meansþ / s.e.m., (WT FVB n¼ 10, K5-UCP3 n¼8). *Indicates significantly different from wild-type FVB, same treatment (Po0.05, Student’s t-test).
(b) Immunoblot for sub-cellular localization of Akt and PTEN in membrane and cytoplasmic fractions from wild-type FVB and K5-UCP3 epidermis
topically treated with 2.5mg TPA or acetone. a-3 integrin and b-actin were used as controls to verify membrane and cytoplasmic fractions, respectively.
(c) Relative quantification of Akt in cytoplasmic and membrane fractions from triplicate separate immunoblotting experiments via densitometry.
Cytoplasmic and membrane fractions were normalized to b-actin and a3-integrin, respectively. Data represent meansþ / s.e.m. (n¼ 3 biological
replicates). *Indicates significantly different from wild-type FVB, same treatment (Po0.05, Student’s t-test). (d) Immunoblot for Akt Ser 473
phosphorylation in wild-type FVB and K5-UCP3 epidermal lysates 6 h following topical treatment with 1-mg Eto ethyl ester or ethyl acetate
(EA, vehicle control). Immunoblotting for b-Actin was used to confirm equal loading.
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overcome stoichiometry at the plasma membrane, resulting in
increased Akt activation even in the absence of increased PIP3
signal in both K5-Akt and K5-UCP3/K5-Akt epidermis. Another
possibility is that the elevated expression and phosphorylation of
Akt may overcome the PP2A hyperactivity we report in Fig. 2g.
Finally, while Akt overexpression fully rescued Akt phosphoryla-
tion, BrdU incorporation and papilloma formation, we still
observed increased latency in papilloma formation, and modest
decreases in carcinoma incidence and multiplicity in K5-UCP3/
K5-Akt mice. Given the global metabolic changes caused by
UCP3 overexpression, we speculate that these effects on tumour
progression may be a result of, pleiotropic mechanisms affecting
additional signalling molecules, however, we chose to focus on
signalling pathways that are well known to play an important role
in tumour promotion by TPA. We believe that the data make
a strong case for Akt inhibition as a central mechanism in
UCP3-induced resistance to tumour formation.
The role of UCPs in carcinogenesis is controversial: while
some studies have reported that upregulation of UCP2, a close
UCP3 homologue, confers tumours a survival advantage41,42,
others have shown that UCP2 expression negatively impacts
tumorigenesis43–46. The only two published cancer studies in
UCP2 null mice have shown opposite effects of UCP2 knockout
in the skin and colon44,47. We have previously shown that
expression of UCP2 kills malignant cells but not a non-
tumorigenic fibroblast cell line48. Furthermore, as shown in
Supplementary Fig. 1c, animals that express an epidermal UCP1
transgene (K5-UCP1) are also resistant to two-stage chemical skin
carcinogenesis, and mice expressing UCP1 specifically in skeletal
muscle are protected from the development of lymphomas and
other age related diseases49. Supporting our data, a recent report
correlated UCP3 expression with Akt downregulation in a high
throughput assay for FOXO1 nuclear localization50. Analysis of






















































Figure 5 | Overexpression of Akt rescues proliferation in K5-UCP3 epidermis. (a) Immunoblot for Akt phosphorylation at Ser 473 in wild-type FVB,
K5-UCP3, K5-Akt and bitransgenic K5-UCP3/K5-Akt epidermal lysates, 4 h following topical treatment with 2.5mg TPA or acetone (vehicle control).
Immunoblotting for b-Actin was used to confirm equal loading. (b) Immunohistochemistry for BrdU labelled cells in wild-type FVB/N, K5-UCP3, K5-Akt, and
bitransgenic K5-UCP3/K5-Akt epidermis following topical treatment with single (1 ) or multiple (4 ) treatments with 2.5mg TPA or acetone. Scale bars,
50m. (c) Quantification of BrdU labelled cells in the basal layer of the interfollicular epidermis (IFE). More than 100 cells from five randomly selected skin
sections (total 4500 cells) were counted from each of n¼ 3 mice per genotype in each treatment group. Error bars represent meansþ / s.e.m.
(n¼ 3 animals per group). *Indicates significantly different from acetone control, same genotype (**Po0.01, ***Po0.0001, one way analysis of variance
(ANOVA) followed by Dunnett’s post hoc analysis), w indicates significantly different from wild-type FVB/N, same treatment (www Po0.0001, one way
ANOVA followed by Dunnett’s post hoc analysis).
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in which UCP3 was among the top 10% of downregulated genes
in cancer tissues compared with normal tissue controls
(Supplementary Table 2). The present study establishes a
molecular mechanism for UCP3-induced cancer prevention,
and shows that enforced UCP3 expression blocks Akt activation
in mouse and human keratinocytes.
The data herein support the argument that mitochondrial
uncoupling may be a uniquely powerful metabolic intervention
because it simultaneously targets a broad repertoire of inter-
connected metabolic and signalling changes essential for
tumorigenesis. Moreover, tumour cells often exhibit profound
metabolic flexibility, using a variety of nutrient sources for both
energy production and biosynthetic reactions and as a result,
many cancers are refractory to singly targeted metabolic
therapies. Mitochondrial uncoupling likely restricts this flexibility
by enforcing the constitutive oxidation of substrates, without
concurrent ATP production. As our data indicate, uncoupled cells
scavenge non-traditional nutrient sources, simultaneously limit-
ing both the intermediates available for biomass production,
along with important second messengers for growth signalling.
Ultimately, the pleotropic effects of mitochondrial uncoupling
provide a strategy to target both cancer cell metabolism and
signalling, and may be a novel and effective therapeutic approach
that circumvents many of the toxic manifestations of traditional
chemotherapeutics.
Methods
Reagents. TPA and OA were purchased from LC Laboratories (Woburn, MA).
Etomoxir ethyl ester (Eto) was purchased from US Biological (Salem, MA).
Trypsin, Trypsin-EDTA, Keratinocyte Serum Free Media (KSFM), Hank’s
Balanced Salt Solution (HBSS), dispase, gentamicin, fungizone, TMRM, MTG and
Lipofectamine 2000 were purchased from Life Technologies (Grand Island, NY).
Acetone, 7,12-dimethylbenz[a]anthracene (DMBA), and all other reagents (unless
otherwise noted) were purchased from Sigma (St. Louis, MO).
Animals. K5-UCP3 FVB/N and K5-Akt FVB/N mice were previously generated
using a bovine keratin 5 (K5) targeting construct as previously described18,33,51,
maintained as hemizygous breeder colonies, and crossed K5-UCP3  K5-Akt to
produce bitransgenic K5-UCP3/K5-Akt mice and littermate controls. FVB/N mice
were purchased from Jackson Laboratories (Bar Harbor, ME). Tg.AC mice were
purchased from Taconic (Hudson, NY). Unless otherwise indicated, all
experiments were performed using sex matched adult, 6–8-week old mice.
All animal husbandry and experiments were carried out in strict accordance to
guidelines defined by the Association for Assessment and Accreditation of
Laboratory Animal Care and approved by the institutional animal research
committees at The University of Texas at Austin and UT-MD Anderson,
Science Park Research Division.
Primary cell culture. All cell lines were cultured under standard conditions of 5%
CO2, 37 C. Primary mouse keratinocytes were collected from the dorsal skin of
adult mice and cultured according to standard methods52. Briefly, mice were killed
by isofluorane inhalation, shaved on dorsal surface, and treated with depilatory
agent. Dorsal skins were excised, and subcutaneous fat was removed and discarded.
Skins were then floated on 0.25% trypsin for 1 h at 37 C followed by an additional
hour at room temperature. Epidermis was divided from the dermis, minced with
scissors and basal keratinocytes were separated by centrifugation in a 22.5% percoll
gradient. Following isolation, primary cells were cultured in collagen-coated plates
with Eagle’s Minimal Essential Medium-2þ 1% FBS (0.05mM Ca2þ ) (Invitrogen,
Carlsbad, CA)52.
Primary neonatal human keratinocytes were isolated and cultured in KSFM for
no more than five passages. To isolate neonatal human keratinocytes cells, human
neonatal skin biopsies were floated overnight on dispase solution (HBSS, 0.75%
sodium bicarbonate, 100mM hepes, 10mgml 1 dispase, 5 mgml 1 gentamicin,
10 ngml 1 fungizone, pH. 7.4) at 4 C. Epidermis was separated from underlying
tissue and placed in Trypsin-EDTA (0.25% trypsin, 1mM EDTA) for 5min at
37 C, then quenched with Dulbecco’s Modified Eagle’s Medium (Corning
Incorporated, Corning, NY))þ 10% FBSþ 0.1% gentamicin and centrifuged at
3,000g for 10min. Epidermal tissue was resuspended vigorously in KSFM before
plating53.
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Figure 6 | Overexpression of Akt rescues tumorigenesis. (a) Timeline for two-stage chemical carcinogenesis tumour experiment. Six-week old mice
(WT FVB n¼ 28, K5-UCP3 n¼ 27, K5-Akt n¼ 29, K5-UCP3/K5-Akt n¼ 18) were shaved dorsally and treated with a single application of DMBA(100 mg)
followed 2 weeks later with bi-weekly applications of TPA (2.5mg) for 26 weeks, as previously described61. Week ‘0’ indicates first TPA treatment.
(b) Tumour development in wild-type FVB, K5-UCP3, K5-Akt, and bitransgenic K5-UCP3/K5-Aktmice indicating total papillomas/mouse, (c) % mice bearing
papillomas, (d) total carcinomas/mouse and (e) % mice bearing carcinomas.
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Flow cytometry and ATP measurement. Primary mouse keratinocytes were
harvested from the dorsal skin of adult mice as described above. For ATP
measurements, 10,000 cells per well were placed in a 96-well plate and ATP levels
were measured in triplicate biological samples using the ApoSENSOR ADP/ATP
Ratio Bioluminescent Assay Kit (BioVision Inc., Milpitas, CA). For flow cytometry
experiments, primary keratinocytes were resuspended in HBSS and stained with
Nile Red (Sigma) at a final concentration of 5 mgml 1 for total cellular lipid
content, or TMRM at 40 nM and MTG at 200 nM for membrane potential and
mitochondrial mass measurements. All flow cytometric analysis was performed in
triplicate biological samples using a BD Biosciences FACS Calibur.
Topical treatments. For all experiments involving topical application of
chemicals, mice were shaved on dorsal skin 48 h before treatment. All experiments
were performed on mice between 6 and 8 weeks of age unless otherwise indicated
(see timelines for tumour experiments). Two to four animals per group were used
for each triplicate experiment. Males and females were divided evenly among
groups. Mice were treated topically with 200ml acetone (vehicle control),
12.5 mgml 1 TPA (2.5-mg dose), 25mM OA (5-nmol dose), or 5mgml 1 Eto
(1-mg dose) and killed at the indicated time points. Dorsal skin biopsies were
collected and fixed for histology or epidermal tissue was collected and used for
immunoblotting as described below.
BrdU labelling and histology. Twenty-four hours after acetone or single TPA
treatment, mice were injected intraperitoneal. with 10mg kg 1 BrdU in sterile
saline, then killed 30min after injection. For 4 TPA treatment, mice received
bi-weekly treatments for 2 weeks (total of four treatments), and were injected with
BrdU and killed 48 h after the final TPA treatment. Dorsal skin biopsies were
collected and fixed overnight in 10% neutral buffered formalin, moved to 70%
ethanol and embedded in paraffin. Sections were stained as previously described54.
Labelling index was calculated as the percentage of basal epidermal cells positive for
BrdU. More than 100 cells from five randomly selected skin sections (total 4500
cells) were counted from each of n¼ 3 mice per genotype in each treatment group.
Primary cell signalling experiments and transfection. For signaling experi-
ments, mouse primary keratinocytes were grown in EMEM-2 with 1% FBS for
48–72 hours following isolation, then serum starved overnight (B18 hours) before
treatment. In NHK cells, transfections were performed using Lipofectamine 2000
reagent, and signaling experiments were performed 72 hours after transfection.
NHK were moved to KSFM without epidermal growth factor (EGF) and bovine
pituitary extract (BPE) supplements 18 hours prior to treatment. For experiments
in both human and mouse cells, keratinocytes were treated with 40 ng/mL EGF
(Gemini Bioproducts, West Sacramento, CA) or 0.0001% BSA (vehicle control,
Fisher Scientific, Pittsburgh, PA), incubated at 37C, 5% CO2 until the indicated
time point, then harvested and used for immunoblotting as described below.
Immunoblotting. Epidermal tissue or whole cell lysates were prepared by lysis in
RIPA buffer (50mM Tris-HCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% SDS,
150mM NaCl and 2mM EDTA) supplemented with protease and phosphatase
inhibitor cocktails (Roche, Nutley, NJ). For membrane localization experiment,
tissue fractionation was performed using differential centrifugation and density
gradients55. Epidermal tissue was homogenized in 250 STMDPS Buffer (250mM
sucrose, 50mM Tris-HCl (pH 7.4), 5mM MgCl2, supplemented with protease and
phosphatase inhibitor cocktails (Roche, Nutley, NJ)) using Dounce homogenizers
with loose followed by tight fitting pestles. Homogenates were centrifuged at 800g
for 15min at 4 C, after which supernatant was transferred to ultracentrifuge tubes
and centrifuged at 100,000g for 1 h at 4 C. Following ultracentrifugation,
supernatant was saved as cytoplasmic fraction and pellets were re-suspended in ME
Buffer (20mM Tris-HCl (pH 7.8), 0.4M NaCl, 15% glycerol, 1.5% Triton X-100
and supplemented with protease and phosphatase inhibitor cocktails) and saved as
membrane fraction55.
Protein lysates were separated by SDS-polyacrylamide gel electrophoresis and
transferred to nitrocellulose. Blots were probed with the following primary
antibodies: a-phospho Akt S473 (Cell Signaling Technology (CST) 9271S, Rabbit,
1:1,000), a-phospho Akt T308 (CST 9275S, Rabbit, 1:1,000), a-Akt (CST 9272S,
Rabbit, 1:1,000), a-phospho FOXO1 S256 (CST 9461, Rabbit, 1:1,000), a-phospho
FOXO1 S319 (CST 2486, Rabbit, 1:1,000), a-phospho GSK-3b S9 (CST 5558,
Rabbit, 1:1,000), a-GSK-3b (CST 12456, Rabbit, 1:1,000), a-phospho TSC2 S939
(CST 3615, Rabbit, 1:1,000), a-phospho mTOR S2448 (CST 5536, Rabbit, 1:1,000),
a-phospho mTOR S2481 (CST 2974, Rabbit, 1:1,000), a-mTOR (CST 2983, Rabbit,
1:1,000), a-phospho 4EBP1 T36/47 (CST 2855, Rabbit, 1:1,000), a-4EBP1( CST
9644P, Rabbit, 1:1,000), a-phospho rs6 T240/244 (CST 5364. Rabbit, 1:1,000),
a-rS6 (CST 2217, Rabbit, 1:1,000), a-phospho eIF4G S1108 (CST 2441, Rabbit,
1:1,000), a-phospho EGFR Y1086 (CST 2220S, Rabbit, 1:1,000), a-EGFR (CST
4267P, Rabbit, 1:1,000), a-phospho p38 MAPK T180/Y182 (CST 9211S, Rabbit,
1:500), a-p38 MAPK (CST 9212, Rabbit, 1:1,000), a-PTEN (CST 9188S, Rabbit,
1:1,000), a-PP2Ac (CST 2259, Rabbit, 1:1,000), a-PP2Aa (CST 2041P, Rabbit,
1:1,000), a-phospho ERK T202/Y204 (CST 4370, Mouse, 1:1,000), a-ERK (CST
9102, Rabbit, 1:1,000), a-phospho p90 RSK T359/S363 (CST 9344, Rabbit, 1:1,000),
a-p90 RSK (CST 9347, Rabbit, 1:1,000), a-PKCa (CST 2056, Rabbit, 1:1,000),
a-b-Actin (CST 4970S, Rabbit, 1:2,000), (CST, Danvers, MA), a-Cyclin D1
(Santa Cruz Biotechnology (SC)-753, Rabbit, 1:200), a-Cyclin A (SC-596, Rabbit,
1:200), a-p21 (SC-6246, Mouse, 1:200), a-p27 (SC-1641, Mouse, 1:200), a-a
tubulin (SC-51500, Mouse, 1:200) a-a3 Integrin (AB1920, Rabbit, 1:500,
Chemicon, Billerica, MA) and a-UCP3 (Rabbit, 1:2,000, custom made by
Washington Biotechnology, Simpsonville, MD). Following primary antibody, blots
were incubated with a-rabbit-horseradish peroxidase (HRP) (NA934V, Donkey,
1:3000, GE Healthcare, Piscataway, NJ) or a-mouse-HRP (NA931V, Sheep, 1:3,000,
GE Healthcare, Piscataway, NJ), and developed using chemiluminescent substrate
(Thermo Scientific, Rockford, IL). Results are representative of three separate
experiments. Uncropped western blots are shown in Supplementary Fig. 8.
PP2A activity assay. PP2A was immuno-precipitated using primary a-PP2Ac
(CST 2259, Rabbit, 1:, Millipore, Billerica, MA), incubated with a target
phospho-peptide and free phosphate release was measured via Malachite Green
assay per the manufacturer’s instructions (Millipore, Billerica, MA).
ROS measurement. ROS production by isolated mitochondria was measured
using Amplex Red per the manufacturer’s instructions (Life Technologies, Grand
Island, NY). Mitochondria from wild type and K5-UCP3 epidermis were suspended
in a buffer containing 5mM MOPS (pH 7.4), 70mM sucrose and 220mM man-
nitol and mitochondrial protein concentration was determined using a BCA pro-
tein assay (Pierce Biotechnology, Rockford, IL). Mitochondrial protein (5 mg) per
well were incubated in a reaction mixture containing 50 mM Amplex Red,
0.2 Uml 1 HRP, and 30Uml 1 SOD at room temperature for 30min, protected
from light56. Superoxide dismutase was added to convert all superoxide into
H2O2. Fluorescence was recorded using a microplate reader (VICTOR 3V;
Pelkin Elmer, Waltham, MA) with 531-nm excitation and 595-nm emission
wavelengths.
20 ,70-dichlorodihydrofluorescein diacetate (Life Technologies, Grand Island,
NY) and dihydroehidium (Life Technologies, Grand Island, NY) were used to
detect cellular hydrogen peroxide and superoxide, respectively. Isolated
primary keratinocytes were incubated with HBSS containing 5 mM
20,70-dichlorodihydrofluorescein diacetate or dihydroehidium. Fluorescence was
analysed by flow cytometric analysis using a BD Biosciences FACS Calibur.
Treatment with 10-mM succinate,10-mM antimycin A, or their combination was
used to stimulate ROS production.
The redox state of Akt and PP2A was determined by analysis of cell extracts
pre-incubated with AMS (4-acetamido-40-maleimidylstilbene-2,20-disulfonic acid).
For AMS labelling experiments, cells were precipitated with 10% ice-cold
trichloroacetic acid for 30min at 4 C and centrifuged at 12,000g for 30min to
collect precipitated protein. Protein pellets were re-suspended in 100% acetone and
incubated at 4 C for 30min. Following centrifugation at 12,000g for 10min, the
acetone was removed and protein pellets were dissolved in 20mM Tris/HCl,
pH 8.0, containing 15-mM AMS and incubated at room temperature (25 C) for
3 h (ref. 56). Akt and PP2A redox forms were separated by SDS-polyacrylamide gel
electrophoresis in the presence of non-reducing loading buffer. Treatments with
dithiothreitol or hydrogen peroxide were used to demonstrate reduced vs oxidized
state of each protein.
Metabolomic analysis. For metabolic profiling, mice (n¼ 6 per genotype, age and
sex matched) were fasted for 5 h before sample collection to control for metabolic
variation due to feeding, then killed via cervical dislocation. Dorsal skin biopsies
were taken and epidermal tissue was collected as described above. Samples were
flash frozen in liquid N2 and stored at  80 C until processed.
Unbiased metabolomic profiling analysis was performed by Metabolon
(Durham, NC) according to their standard procedures57. Briefly, samples were
prepared with the automated MicroLab STAR system from Hamilton Company
using an aqueous methanol extraction process to remove proteins while allowing
maximum recovery of small molecules. Aliquots of the resulting extract were
analysed by ultrahigh performance liquid chromatography/mass spectrometry
(UPLC/MS; positive mode), UPLC/MS (negative mode), or gas chromatography/
MS. Raw data were extracted, peak identified, processed against quality control
standards and normalized to total protein content by Metabolon. Compounds were
identified by comparison with a library of 42,400 purified standards’ analytical
characteristics on Metabolon’s LC and gas chromatography platforms. Compounds
with a P value o0.05 in a Welch’s two-sample t-test were considered to be
significantly different between genotypes.
Fatty acid oxidation and oximetry. Endogenous fatty acid oxidation was deter-
mined in epidermal tissue in Kreb’s Ringer Buffer (Sigma), using a Clark-type
electrode from Instech (Plymouth Meeting, PA). Saturated oxygen concentration
was assumed to be 217 nMol/ml 1 for all readings. Respiratory rates were mea-
sured at linear regions on the curve under conditions of no treatment and
40-mM Eto. Fatty acid driven respiration was calculated as the basal respiration
minus respiration after Eto treatment. To assess mitochondrial function in K5-Akt
epidermis, respiratory rates were measured at linear regions on the curve under
conditions of no treatment, 1 mgml 1 oligomycin, and 250-mM 2,4-dinitrophenol
to determine state 3, state 4, and maximal respiration, respectively.
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Gene ontology analysis. Gene expression analysis of K5-UCP3 and wild-type
dorsal skin was performed by Illumina microarray. RNA was isolated from
untreated dorsal skin directly after isolation from 7-week-old male WT FVB and
K5-UCP3 mice (n¼ 3) using TRIzol Reagent (Invitrogen, Carlsbad, CA) followed
by a clean-up procedure using the QIAGEN RNeasy kit (QIAGEN, Inc.). Labelling
was achieved by incorporation of biotin-16-UTP (Perkin Elmer Life and Analytical
Sciences, Boston, MA) present at a ratio of 1:1 with unlabelled UTP. Labelled,
amplified material (700 ng per array) was hybridized to the Illumina Mouse-6_V1
BeadChip according to the manufacturer’s instructions (Illumina, Inc., San Diego,
CA). Arrays were scanned with an Illumina Bead array Reader confocal scanner
and data processing and analysis was performed using the Illumina BeadStudio
software. These data have been deposited in NCBI’s Gene Expression Omnibus58
and are accessible through GEO Series accession number GSE71038.
Gene ontology analysis was performed using the functional annotation tool
DAVID (http://niaid.abcc.ncifcrf.gov/home.jsp)59,60. Significantly up-regulated
genes (calculated by Illumina DiffScore, a proprietary algorithm that builds an
error model based on the bead s.d., Po0.01, DiffScore±22) in K5-UCP3 dorsal
skin were submitted to the DAVID website. Identified terms and gene names are
shown in Supplementary Table 1.
Tumour experiments. For Tg.AC tumour experiment, 16-week-old mice (Tg.AC
n¼ 20, K5-UCP3/Tg.AC n¼ 20) were shaved dorsally and treated with bi-weekly
applications of TPA (2.5 mg) for 2 weeks for a total of four treatments61. For
K5-UCP3/K5-Akt rescue experiment, adult (6–8 week) WT FVB/N (n¼ 28) and
hemizygous K5-UCP3 (n¼ 27), K5-Akt (n¼ 29) and K5-UCP3/K5-Akt (n¼ 18)
littermates were initiated topically on shaved dorsal skin with a single application
of DMBA (100 mg) followed two weeks later with bi-weekly applications of TPA
(2.5mg) for 26 weeks62. In both experiments, sample size was chosen based on our
previous empirical experience, which has shown that to detect differences ofB30%
in tumour burden with a power of 80 (at P¼ 0.05) requires 25–30 mice/group
(2-tailed unpaired t-test), while larger differences are detectable with smaller n.
An even ratio of males and females between genotypes was ensured to control for
sex-specific effects. Mice were scored weekly for tumour incidence (percentage of
mice with skin tumours) and tumour multiplicity (number of skin tumours per
mouse). Mice were killed if moribund, if any individual tumour reached a diameter
of 41 cm, or at the termination of the experiment. Papillomas were distinguished
histologically from carcinomas based on integrity of the basement membrane of the
epidermis (invasion into the dermis and subcutis), overall cell morphology (well
versus poorly differentiated) and the presence of other identifying characteristics
(for example, keratin pearls, immune cell infiltration and angiogenesis).
Statistics. Analysis of variance comparisons between genotypes were analysed by
Student’s t-test or single factor analysis of variance followed by Dunnett’s post hoc
test, with Po0.05 set a priori as statistically significant.
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